Table 2.

(Continued)

Abbreviations: 5-FU, 5-fluorouracil; α-GalCer, α-galactosylceramide; Ab, antibody; AdV, adenovirus-transduced; Ag, antigen; AML, acute myeloid leukemia; β-gal, β-galactosidase; beige mice, lack NK cell function; CNS, central nervous system; CpG, DNA sequence TLR9 ligand; CTL, cytotoxic T lymphocyte; D1, splenic immature dendritic cell line; DC, bone marrow-derived dendritic cell; Dex, DC-derived exosomes; DLN, draining lymph nodes; f.p., footpad; gp, glycoprotein; i.c., intracranial; i.d., intradermal; iDC, immature DC; IL, interleukin; i.p., intraperitoneal; i.t., intratumoral; KO, knockout; LAK, lymphokine-activated killer; LLC, Lewis lung cancer; LPS, lipopolysaccharide TLR4 ligand; MART-1, melanoma antigen recognized by T cells; MBL-2, murine lymphoma cell line; mDC, mature DC; MO5, B16F10 melanoma derivative; NK cell, natural killer cell; NOG mice, nonobese diabetic severe combined immunodeficient IL2Rγ^null mice lacking lymphocytes; pDC, plasmacytoid DC; rSeV, recombinant Sendai virus; SV40, simian virus 40; TAA, tumor-associated antigen; TLR, Toll-like receptor; TRAIL, tumor necrosis factor-related apoptosis-inducing ligand; VSV, vesicular stomatitis virus-transduced; YAC-1, NK-sensitive mouse T cell lymphoma.